At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
LNK01001 Dose A +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficiency and Safety of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating LNK01001 Dose A, LNK01001 Dose B, and 1 other intervention for Atopic Dermatitis. Completed, enrolled 150 participants across 1 site.
Detailed Summary
Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJan 2022
Primary CompletionJun 2023
First PostedOct 2023
TodayJul 2026
First PostedOct 17, 2023
Enrollment StartJan 26, 2022
Primary CompletionJun 14, 2023
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 2.7 years ago
Interventions
LNK01001 Dose Adrug
Capsules taken orally
LNK01001 Dose Bdrug
Capsules taken orally
placebodrug
Capsules taken orally